ASPHD1

Across TCGA pan-cancer cohorts, ASPHD1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ASPHD1 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ASPHD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ASPHD1 expression acts as an unfavorable survival marker.

ESCA, LUSC, and SKCM are the cancer types where ASPHD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	6	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LUAD	DFS	Median	All	0.244	0.767	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ASPHD1–ESCA (OS)

Open the ESCA breakdown →